Author: yuvcc

At RJH Biosciences, we develop non-viral, polymer-based nucleic acid delivery systems designed for efficient transfection of primary and hard-to-transfect cells. Our platform enables robust delivery of a range of nucleic acids with consistent performance across diverse cell types and animal models, outperforming commercial comparators. Our biocompatible reagents enable safe modification of cells in culture, and… Continue reading July 2026 | “Safety-First” Transfection Reagents: Validated, Trusted Technology

At RJH Biosciences, we develop non-viral, polymer-based nucleic acid delivery systems designed for efficient transfection of primary and hard-to-transfect cells. Our platform enables robust delivery of a range of nucleic acids with consistent performance across diverse primary cells. The RJH reagents achieve strong and reproducible gene expression in primary and murine cell models, outperforming commercial… Continue reading May 2026 | Efficient Nucleic Acid Delivery in Primary Cells

RJH Biosciences provides polymer-based transfection solutions supporting RNA and DNA delivery across cell lines, primary cells, and in vivo models. This edition highlights recent client work, including high-throughput polymer screening for siRNA delivery and functional siRNA library screening in human breast cancer and fibroblast cells. Screening for Optimal Delivery Formulation Three polymeric delivery systems were… Continue reading March 2026 | Delivery Insights: RJH Biosciences Contract Services

Polymer-Based Solutions for Effective In Vivo mRNA Delivery At RJH Biosciences, we develop non-viral, polymer-based delivery platforms engineered for efficient and reproducible mRNA delivery across in vivo biological systems. Our technologies support functional mRNA expression in animal models and are designed to enable systemic delivery, consistent performance, and broad applicability across research and therapeutic development… Continue reading February 2026 | Advancing mRNA Delivery In Vivo: New Animal Study Results

At RJH Biosciences, we develop non-viral, polymer-based transfection technologies optimized for delivery of nucleic acids across a wide range of modalities. Our platforms enable efficient and reproducible delivery in established cell lines, primary cells, and in vivo models, supporting fundamental research as well as therapeutic development. Overview of RJH Biosciences transfection reagents across nucleic acid… Continue reading January 2026 | Polymer-Based Solutions for Strong RNA and DNA Delivery Across Biological Systems

Learn how our polymer-based transfection reagents enable CRISPR activity and open new possibilities for gene editing. Engineered for high-efficiency gene editing. GFP Knockout CRISP-Fect: Functional Knockout Validated by qPCR About CRISP-Fect and Genome Editing Delivery CRISP-Fect is a polymer-based transfection platform developed by RJH Biosciences to support efficient delivery of CRISPR components, including Cas9 mRNA, sgRNA, and… Continue reading December 2025 | CRISP-Fect: A Polymer-Based Platform for Efficient CRISPR Genome Editing

Strong mRNA expression and siRNA silencing across multiple organs demonstrate the superior performance and reliability of RJH’s delivery technology. Robust Multi-Organ mRNA Expression mRNA-Fect Ultra enabled robust in vivo luciferase mRNA expression following intraperitoneal administration. Whole-animal images (left) and organ-level luminescence quantitation (right) show high, consistent expression across key tissues. Efficient In Vivo siRNA Delivery… Continue reading October 2025 | Proven In Vivo Performance for mRNA and siRNA Delivery

Efficient delivery leads to protein expression and functional outcomes from primary human blood cells. Effective mRNA Delivery to PBMCs PBMCs were transfected with GFP mRNA using mRNA-Fect ULTRA and compared against a leading commercial reagent. mRNA-Fect ULTRA achieved markedly higher GFP expression demonstrating superior efficiency in these hard-to-transfect immune cells. PBMCs Secrete Functional TRAIL PBMCs… Continue reading September 2025 | mRNA Delivery to Drive PBMC Functionality